Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07728383

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

Conditions: Obesity & Overweight

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: No

Phase: PHASE4

Enrollment: 40

Sponsor: Gila Therapeutics, Inc.

Location: Clinical Research Institute of Minnesota Minneapolis Minnesota

Summary

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

Eligibility Criteria

Inclusion Criteria: * Body Mass Index 30 to 45 Exclusion Criteria: * Type 2 Diabetes Mellitus * Multiple Endocrine Neoplasia Type 2 * Medullary thyroid cancer

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07728383). StuddyBuddy aggregates publicly available trial information.